A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

NCT00106431 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
102
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene

Collaborators